Navigation Links
Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis
Date:3/13/2008

ECUBLENS, SWITZERLAND, March 13 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX; TSX: NRM), announces that the Company is taking new initiatives to pursue the drug development program for its investigational product candidate, eprodisate (KIACTA(TM)), to obtain market approval for the treatment of Amyloid A (AA) amyloidosis. Neurochem's decision to build upon its eprodisate (KIACTA(TM)) asset and take steps to initiate a second Phase III clinical trial is based principally on the fact that AA amyloidosis is a life-threatening disease for which there is no specific treatment, on the data obtained from the first Phase II/III clinical trial, which yielded promising efficacy results on the study endpoints, on the benign safety profile of eprodisate (KIACTA(TM)) in patients diagnosed with AA amyloidosis, and on its discussions with the regulatory agencies and related scientific advisory committees. As part of the approval process for the investigational product candidate, both the regulatory agencies in the United States and in the European Union recommended an additional confirmatory efficacy Phase III clinical trial, which will have a target significance level (p-value) of 0.05 rather than the p-value of 0.01, which had been required for an approval based on a single efficacy study. Based on these recommendations, the Company will enter into discussions with the U.S. Food and Drug Administration (FDA) and with the European Medicines Agency (EMEA) to reach agreement on the terms for an approval of eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis. As part of this strategic decision, the Company is also announcing that it is withdrawing its current mark
'/>"/>

SOURCE NEUROCHEM INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Neurochem reports results for third quarter of fiscal 2007
2. Neurochem announces departure of Dr. Philippe Calais, President, Global Business
3. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
4. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
5. Neurochem to present at JPMorgan Healthcare Conference
6. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
7. Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
8. Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
9. Neurochem announces departure of two members of management team
10. DSS Research Moves Corporate Office
11. Sutter Moves to Reduce Public Accountability, Slash Hospital Beds
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3IEEE USA President endorses national innovation strategy 10050 1Utah ethicist heads stem cell panel 10048 1Utah ethicist heads stem cell panel 10048 2Utah ethicist heads stem cell panel 10048 3New beryllium reference material for occupational safety monitoring 10046 1New beryllium reference material for occupational safety monitoring 10046 2